TY - JOUR T1 - Age-dependent heterogeneity of lymph node metastases and survival in breast cancer: A population-based study JF - medRxiv DO - 10.1101/2021.01.21.21250252 SP - 2021.01.21.21250252 AU - Michael Behring AU - Sumit Agarwal AU - Prachi Bajpai AU - Amr Elkholy AU - Hyung-Gyoon Kim AU - Shi Wei AU - Sadeep Shrestha AU - Upender Manne Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/23/2021.01.21.21250252.abstract N2 - Background For several cancers, including those of the breast, young age at diagnosis is associated with an adverse prognosis. Although this effect is often attributed to heritable mutations such as BRCA1/2, the relationship between pathologic features, young age of onset, and prognosis for breast cancer remains unclear. In the present study, we highlight links between age of onset and lymph node metastasis (NM) in US women with breast cancer.Methods Case listings from Surveillance, Epidemiology, and End Result (SEER) 18 registry data for women with breast cancer, which include information on race, were used. NM and its associated outcomes were evaluated for a subset of women with receptor subtype information and then compared against a larger, pre-subtype validation set of data from the same registry. Age of diagnosis was a 5-category variable; under 40 years, 40-49 years, 50-59 years, 60-69 years and 70+ years. Univariate and adjusted multivariate survival models were applied to both sets of data.Results As determined with adjusted logistic regression models, women under 40 years old at diagnosis had 1.55 times the odds of NM as women 60-69 years of age. The odds of NM for (HR = hormone receptor) HR+/HER2+, HR-/HER2+, and triple-negative breast cancer subtypes were significantly lower than those for HR+/HER2-. In subtype-stratified adjusted models, age of diagnosis had a consistent trend of decreasing odds of NM by age category, most noticeable for HR+ subtypes of luminal A and B. Univariate 5-year survival by age was worst for women under 40 years, with NM attributable for 49% of the hazard of death from cancer in adjusted multivariate models.Conclusions Lymph node metastasis is age-dependent, yet not all molecular subtypes are clearly affected by this relationship. For <40-yr-old women, NM is a major cause for shorter survival. When stratified by subtype, the strongest associations were in HR+ groups, suggesting a possible hormonal connection between young age of breast cancer onset and NM.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported, in part, by grant 5U54CA118948 (NCI/NIH) and institutional/departmental impact funds to UM, and by CA047888 (NCI/NIH), the UAB Cancer Prevention and Control Training Program to MB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is exempt research from secondary dataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available in SEER*stat database https://seer.cancer.gov/seerstat/download/ All data will be made available.NMnodal metastasis;SEERSurveillance, Epidemiology, and End Results;TNMtumor, node, and metastasis;HRhormone receptor;ERestrogen receptor;PRprogesterone receptor;ERBB2/HER2human epidermal growth factor receptor 2;TNBCtriple-negative breast cancer. ER -